期刊
JOURNAL OF CELLULAR BIOCHEMISTRY
卷 121, 期 7, 页码 3465-3478出版社
WILEY
DOI: 10.1002/jcb.29621
关键词
BHLHE40-AS1; breast cancer progression; ductal carcinoma in situ (DCIS); IL-6; ILF3; long noncoding RNA; STAT3
资金
- National Cancer Institute [1R21CA185460-01]
- Cancer Prevention and Research Institute of Texas [RP170005]
- National Institute of Environmental Health Sciences [1P30ES030285-01]
- Susan G. Komen [CCR17481765]
- U.S. Department of Defense [W81XWH-15-1-0495]
- Breast Cancer Alliance
- NIH [CA125123, CA168524]
- Breast Cancer Research Foundation
Ductal carcinoma in situ (DCIS) is a nonobligate precursor to invasive breast cancer. Only a small percentage of DCIS cases are predicted to progress; however, there is no method to determine which DCIS lesions will remain innocuous from those that will become invasive disease. Therefore, DCIS is treated aggressively creating a current state of overdiagnosis and overtreatment. There is a critical need to identify functional determinants of progression of DCIS to invasive ductal carcinoma (IDC). Interrogating biopsies from five patients with contiguous DCIS and IDC lesions, we have shown that expression of the long noncoding RNA BHLHE40-AS1 increases with disease progression. BHLHE40-AS1 expression supports DCIS cell proliferation, motility, and invasive potential. Mechanistically, BHLHE40-AS1 modulates interleukin (IL)-6/signal transducer and activator of transcription 3 (STAT3) activity and a proinflammatory cytokine signature, in part through interaction with interleukin enhancer-binding factor 3. These data suggest that BHLHE40-AS1 supports early breast cancer progression by engaging STAT3 signaling, creating an immune-permissive microenvironment.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据